Delivering on a promise made last year, the American Hospital Association and other hospital groups filed suit Wednesday in a federal district court against U.S. Health and Human Services (HHS) Secretary Alex Azar over a change in Medicare reimbursement for 340B drugs. Read More
Civica Rx, of Salt Lake City, previously known as Project Rx, is a new, not-for-profit generic drug company aimed at helping patients by addressing shortages and high prices of lifesaving medications. (See BioWorld, Jan. 29, 2018.) Read More
Nicox SA, of Sophia Antipolis, France, said it confidentially submitted a draft registration statement on form F-1 to the SEC relating to a proposed offering of American Depository Shares representing the company's ordinary shares in the U.S. The offering has not yet been priced. Read More
An Australian study has discovered several new lipid molecules that may represent new biomarkers and/or potential therapeutic targets for atrial fibrillation (AF) and heart failure (HF). Read More
With immunotherapies inspiring reason for hope against what have been hopeless cancers, researchers are looking for ways to make preclinical development more predictive of how a potential treatment will work in people. Read More
Not to be confused with a round-the-clock operation, Twentyeight-Seven Therapeutics Inc. (28-7) managed its time over the past two years by quietly assembling a team of scientific luminaries focused on the task of modulating non-coding RNA (ncRNA) as the platform to discover and develop small molecules that increase levels of the tumor suppressor microRNA (miRNA), Let-7, in cancer indications. Those efforts resonated with a stable of investors, including seed investor MPM Capital, which co-led with Novartis Venture Fund 28-7's $65 million series A. Others in the syndicate included JJDC Inc., Vertex Ventures HC, Longwood Fund, and Astellas Venture Management. Read More
BOSTON – The intersection of gene therapy with rare disease drug development was one topic explored by panelists at Biopharm America, who surveyed new business models, fretted over reimbursement, and took stock of the favorable (so far) regulatory climate. Read More
Aurobindo Pharma USA Inc. has agreed to pay Novartis AG's generics division, Sandoz Inc., up to $1 billion for a basket of dermatology and generic oral medicines that the Swiss drugmaker is divesting as it pursues growth amid increasingly challenging forces in the generics space. With an up-front purchase price of $900 million plus up to $100 million in potential earn-outs, the deal will add about 300 products to Aurobindo's portfolio, including projects in development, as well as new U.S.-based commercial and manufacturing capabilities. Read More
